Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Apitegromab: Phase 3 SAPPHIRE in SMA# The Phase 3 SAPPHIRE trial represents the most advanced clinical success for any myostatin-targeted therapy: 188 patients aged 2-21 with Type 2 or 3 SMA, all receiving background SMN-targeted treatment Primary endpoint met : Clinically meaningful improvement on HFMSE (Hammersmith Functional Motor Scale Expanded) versus placebo (p=0.0192), with a mean difference of 1.8 points Functional responders : 30.4% of apitegromab patients achieved 3 or more point HFMSE improvement versus 12.5% placebo Upper limb function : Consistent improvement measured by RULM (Revised Upper Limb Module) Published in The Lancet Neurology This is notable because it overcomes the historical "mass-function disconnect" that plagued earlier myostatin inhibitors -- apitegromab improved actual motor function, not just muscle mass
As with Mounjaro, Wegovy side effects tend to improve once a stable dose is reached
doi: 10.1177/1933719115592713 157 GuptaSGoldbergJMAzizNGoldbergEKrajcirNAgarwalA
Because L-carnitine plays a vital role in how the body converts fat into usable energy, levels can influence how efficiently energy is created during rest and exercise
